This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), BioCryst (BCRX)

Tipranks - Tipranks - Fri May 8, 6:04AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Revolution Medicines (RVMD), BioCryst (BCRX) and Castle Biosciences (CSTL) with bullish sentiments.

Claim 55% Off TipRanks

Revolution Medicines (RVMD)

In a report released today, Kelsey Goodwin from Piper Sandler maintained a Buy rating on Revolution Medicines, with a price target of $172.00. The company’s shares closed last Wednesday at $151.07.

According to TipRanks.com, Goodwin is a 5-star analyst with an average return of 54.3% and a 71.6% success rate. Goodwin covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Janux Therapeutics Inc, and Olema Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $177.94 average price target, implying a 21.3% upside from current levels. In a report issued on April 22, Guggenheim also maintained a Buy rating on the stock with a $175.00 price target.

See today’s best-performing stocks on TipRanks >>

BioCryst (BCRX)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on BioCryst, with a price target of $32.00. The company’s shares closed last Wednesday at $8.83, close to its 52-week high of $9.50.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 26.4% and a 55.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Madrigal Pharmaceuticals. ;'>

BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $22.71, a 163.2% upside from current levels. In a report released yesterday, TipRanks – OpenAI also upgraded the stock to Buy with a $10.00 price target.

Castle Biosciences (CSTL)

In a report released today, Subbu Nambi from Guggenheim maintained a Buy rating on Castle Biosciences, with a price target of $47.00. The company’s shares closed last Wednesday at $24.75.

According to TipRanks.com, Nambi is a 4-star analyst with an average return of 18.0% and a 50.5% success rate. Nambi covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, BillionToOne, Inc. Class A, and Adaptive Biotechnologies. ;'>

Currently, the analyst consensus on Castle Biosciences is a Strong Buy with an average price target of $45.75.

Read More on RVMD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).